Independence Blue Cross to stop covering Wegovy, Ozempic as weight loss drugs in 2025
Independence Blue Cross said starting Jan. 1 it will only be covering GLP-1 agonists — commonly sold under brand names like Wegovy and Ozempic — when prescribed for their Food and Drug Administration -approved uses. That includes type 2 diabetes and cardiovascular disease.
In Michigan, the state’s largest insurer has tightened restrictions around medications like Wegovy. Patients are panicking.
Investors and analysts had eagerly awaited this data as a test of Novo’s case that it has a strong pipeline of drugs to ...
Connecticut law requires Medicaid to cover certain weight loss drugs, but officials say it hasn't been happening due to cost ...
The history of weight loss medicines reads like a Greek tragedy. However, the biology behind the new GLP-1 agonists suggests ...
Independence Blue Cross joins other insurance companies in restricting coverage of Wegovy and Ozempic to Type 2 diabetes and ...
Popular weight-loss drugs like Wegovy and Zepbound are boosting the use of healthcare in the U.S., leading to an uptick in ...
On today’s Big Take podcast, Bloomberg reporter Madison Muller joins host Sarah Holder to share what she’s learned about the ways telehealth can make it easier for people to get prescriptions that ...
Unless you’ve been living under a rock, you know that weight-loss drugs are the talk of the town. GLP-1 drugs, in particular, ...
More than half a million people are buying weight-loss injections online because of the “slow” rollout of the drugs by the ...
Results for its new CagriSema drug, while promising, fell below expectations, sending shares of the pharmaceutical giant down ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback